A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

Trial Profile

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TELECAST
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2018 According to a Lexicon Pharmaceuticals media release, data from the study will be presented at the upcoming 15th Annual European Neuroendocrine Tumor Society Conference
    • 20 Jan 2018 Results assessing time to onset of sustained bowel movement frequency improvement and worsening presented at the 2018 Gastrointestinal Cancers Symposium
    • 02 Jan 2018 According to a Lexicon Pharmaceuticals media release, data from the study will be presented at the upcoming 2018 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top